JPH0759808A - Blood circulation promotion type hydrous plaster - Google Patents
Blood circulation promotion type hydrous plasterInfo
- Publication number
- JPH0759808A JPH0759808A JP5212634A JP21263493A JPH0759808A JP H0759808 A JPH0759808 A JP H0759808A JP 5212634 A JP5212634 A JP 5212634A JP 21263493 A JP21263493 A JP 21263493A JP H0759808 A JPH0759808 A JP H0759808A
- Authority
- JP
- Japan
- Prior art keywords
- plaster
- parts
- blood circulation
- stimulant
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 45
- 230000017531 blood circulation Effects 0.000 title claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229920001971 elastomer Polymers 0.000 claims abstract description 17
- 239000000806 elastomer Substances 0.000 claims abstract description 16
- 239000003921 oil Substances 0.000 claims abstract description 14
- 235000019198 oils Nutrition 0.000 claims abstract description 14
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims abstract description 12
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 11
- 229960002389 glycol salicylate Drugs 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 5
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 5
- 238000010792 warming Methods 0.000 claims description 21
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 19
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 19
- 230000001737 promoting effect Effects 0.000 claims description 13
- 229940007061 capsicum extract Drugs 0.000 claims description 9
- 239000001943 capsicum frutescens fruit extract Substances 0.000 claims description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 229960000846 camphor Drugs 0.000 abstract description 2
- 229940116257 pepper extract Drugs 0.000 abstract description 2
- 229920000428 triblock copolymer Polymers 0.000 abstract 2
- 230000001133 acceleration Effects 0.000 abstract 1
- 230000001804 emulsifying effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 14
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- -1 vinyl compound Chemical class 0.000 description 6
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 5
- 235000012211 aluminium silicate Nutrition 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 231100000046 skin rash Toxicity 0.000 description 5
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 229920001083 polybutene Polymers 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 235000010215 titanium dioxide Nutrition 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241000208293 Capsicum Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000010721 machine oil Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 150000003097 polyterpenes Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000001931 thermography Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- KPAPHODVWOVUJL-UHFFFAOYSA-N 1-benzofuran;1h-indene Chemical compound C1=CC=C2CC=CC2=C1.C1=CC=C2OC=CC2=C1 KPAPHODVWOVUJL-UHFFFAOYSA-N 0.000 description 1
- LRTOHSLOFCWHRF-UHFFFAOYSA-N 1-methyl-1h-indene Chemical compound C1=CC=C2C(C)C=CC2=C1 LRTOHSLOFCWHRF-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- JWSHIRSLWXBMLK-UHFFFAOYSA-N O.O.O.O.O.O.O.O.O.O.O.O.[K] Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[K] JWSHIRSLWXBMLK-UHFFFAOYSA-N 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KBAYQFWFCOOCIC-GNVSMLMZSA-N [(1s,4ar,4bs,7s,8ar,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,7,8,8a,9,10,10a-dodecahydrophenanthren-1-yl]methanol Chemical compound OC[C@@]1(C)CCC[C@]2(C)[C@H]3CC[C@H](C(C)C)C[C@H]3CC[C@H]21 KBAYQFWFCOOCIC-GNVSMLMZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010727 cylinder oil Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- CRBREIOFEDVXGE-UHFFFAOYSA-N dodecoxybenzene Chemical compound CCCCCCCCCCCCOC1=CC=CC=C1 CRBREIOFEDVXGE-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonanoic acid vanillylamide Natural products CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、肩こり、神経痛、慢性
化した関節痛等に有用な、血行促進作用に優れた膏体に
関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a plaster which is useful for stiff shoulders, neuralgia, chronic arthralgia and the like and which has an excellent blood circulation promoting action.
【０００２】[0002]
【従来の技術・発明が解決しようとする課題】従来、肩
こり、神経痛、慢性化した関節痛等に対して、温める療
法に用いられる、温感刺激剤を配合したパップ剤、プラ
スター剤が多く販売されてきている。[Prior Art] [Problems to be Solved by the Invention] Conventionally, a lot of poultices and plasters containing a warming sensation stimulant, which are used for warming therapy for stiff shoulders, neuralgia, chronic joint pain, etc., are sold. Has been done.
【０００３】パップ剤は、ポリアクリル酸およびその塩
類、ゼラチン、ポリエチレンオキサイド等の水溶性ポリ
マー、グリセリン、プロピレングリコール等の保湿成
分、カオリン、チタン白等の賦形剤、および多量の水が
配合されたものを基剤として用い、これに薬剤を分散、
混和させて膏体とし、支持体上に伸展させたものが一般
的である。このような基剤中に、ノニル酸ワニリルアミ
ド、トウガラシエキス等の温感刺激剤を配合しても、上
記基剤中に多量の水分が連続相として含まれているた
め、水の蒸発により貼付部位が冷却され、血行促進作用
を阻害することになり、温めて治療する効果を全く期待
することができない。また、この基剤では、皮膚に対す
る粘着力が弱いために固定用の補助テープを使用する
が、操作の煩雑さおよび固定時の違和感等の欠点があ
る。The poultices contain polyacrylic acid and salts thereof, water-soluble polymers such as gelatin and polyethylene oxide, moisturizing ingredients such as glycerin and propylene glycol, excipients such as kaolin and titanium white, and a large amount of water. Used as a base, the drug is dispersed in it,
It is common to mix the mixture into a plaster and spread it on a support. Even if such a base contains a warming stimulant such as nonyl acid vanillyl amide or capsicum extract, since a large amount of water is contained as a continuous phase in the base, the sticking site by evaporation of water It is cooled, and the blood circulation promoting effect is inhibited, and the effect of warming and treatment cannot be expected at all. Also, with this base, an auxiliary tape for fixing is used because it has a weak adhesive force to the skin, but there are drawbacks such as complexity of operation and discomfort during fixing.
【０００４】プラスター剤は、天然ゴム、合成ゴム等の
ゴム類に、ロジン、エステルガム、石油系樹脂等の粘着
付与成分、流動パラフィン、マシン油等の油成分、カオ
リン、亜鉛華等の賦形剤からなるものを基剤として用
い、これに薬剤を配合させて膏体とし、支持体上に伸展
させたものが一般的である。市販品（プラスター剤）で
の温感刺激剤濃度は、一般に、その膏体全量に対して、
ノニル酸ワニリルアミドで約０．０５〜０．１重量％、
トウガラシエキスで約１〜２重量％で高濃度であり、皮
膚カブレが発生し易い等の欠点がある。また、これらは
ある程度の刺激感を与えることは可能であるが、血行促
進作用が十分に得られず、大きな治療効果を期待するこ
とはできないという欠点がある。The plaster agents are rubbers such as natural rubber and synthetic rubber, tackifying components such as rosin, ester gum and petroleum-based resins, oil components such as liquid paraffin and machine oil, kaolin, zinc flower and the like. It is common to use a base consisting of an agent, mix this with a medicine to form a plaster, and spread it on a support. The concentration of the warming stimulant in a commercial product (plaster agent) is generally based on the total amount of the plaster.
About 0.05 to 0.1% by weight of nonyl vanillylamide,
Pepper extract has a high concentration of about 1 to 2% by weight, and has a defect that skin rash easily occurs. Further, although they can give a feeling of irritation to some extent, they have a drawback in that they cannot obtain a sufficient blood circulation promoting action and a large therapeutic effect cannot be expected.
【０００５】本発明の目的は、低濃度の温感刺激剤量で
十分な血行促進作用を発現しえ、かつ皮膚カブレが少な
く、しかも貼付剤等にした場合に固定用補助テープ等の
不要な粘着性に優れた血行促進型含水膏体を提供するこ
とである。The object of the present invention is to produce a sufficient blood circulation promoting action with a low concentration of a warming stimulant, to reduce skin rash, and to eliminate the need for an auxiliary tape for fixing when used as a patch or the like. (EN) It is intended to provide a blood circulation-promoting hydrous plaster excellent in adhesiveness.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、上記目的
を達成すべく鋭意研究した結果、基剤に温感刺激剤を乳
化、分散させてなり、特定範囲の含水率を有する膏体
が、従来にない優れた作用（血行促進作用等）を示すこ
とを見出した。また、当該膏体は皮膚カブレを生じるこ
とが少なく、しかも粘着性に優れているので、貼付剤等
にした場合に固定用補助テープ等を使用することなく患
部に固定することができることを見出し、本発明を完成
した。Means for Solving the Problems As a result of intensive studies aimed at achieving the above object, the present inventors have found that a temperature-sensing stimulant is emulsified and dispersed in a base and has a water content in a specific range. However, it has been found that it exhibits an unprecedented excellent action (blood circulation promoting action, etc.). Further, since the plaster is less likely to cause skin rash and has excellent adhesiveness, it was found that it can be fixed to an affected area without using a fixing auxiliary tape or the like when it is used as a patch or the like, The present invention has been completed.
【０００７】即ち、本発明は、Ａ−Ｂ−Ａ型ブロック共
重合エラストマー、油成分、粘着付与成分および温感刺
激剤が含有された油性連続相中に水粒子が乳化、分散さ
れてなり、かつその含水率が１０〜５０重量％であるこ
とを特徴とする血行促進型含水膏体である。また、上記
温感刺激剤が、ノニル酸ワニリルアミド、トウガラシエ
キスから選ばれる少なくとも１種である血行促進型含水
膏体である。さらに、温感刺激剤以外の薬効成分とし
て、サリチル酸メチル、サリチル酸グリコール、ｌ−メ
ントール、ｄｌ−カンフル、ハッカ油、酢酸トコフェロ
ールから選ばれる少なくとも１種が配合されてなる血行
促進型含水膏体である。That is, according to the present invention, water particles are emulsified and dispersed in an oily continuous phase containing an ABA type block copolymer elastomer, an oil component, a tackifying component and a warming stimulant, The water content is 10 to 50% by weight, which is a blood circulation promoting hydrous plaster. The warming stimulant is a blood circulation-promoting hydrous plaster which is at least one selected from nonyl acid vanillyl amide and capsicum extract. Further, as a medicinal component other than the warming stimulant, a blood circulation-promoting hydrous plaster body in which at least one selected from methyl salicylate, glycol salicylate, l-menthol, dl-camphor, peppermint oil, and tocopherol acetate is blended. .
【０００８】本発明において用いられるＡ−Ｂ−Ａ型ブ
ロック共重合エラストマー（以下、ブロックエラストマ
ーと称する）は、硬質重合体Ａと軟質重合体Ｂ（Ａ：Ｂ
＝１０〜６５：９０〜３５重量％、好ましくはＡ：Ｂ＝
１５〜３０：８５〜７０重量％）からなるＡ−Ｂ−Ａ型
構造のエラストマーである。Ａブロックは、例えばスチ
レン、メチルスチレン等のビニル化合物の硬質重合体
で、そのガラス転移温度が７０℃以上（好ましくは９０
〜１００℃）のもので、約１０００〜５０００００（好
ましくは１００００〜１０００００）の平均分子量を有
する重合体が有用である。また、Ｂブロックは、例えば
ブタジエン、イソプレン等の共役ジエン化合物の軟質重
合体で、そのガラス転移温度が−１００〜３０℃（好ま
しくは−９０〜−７０℃）のもので、約４５００〜１０
０００００（好ましくは５００００〜５０００００）の
平均分子量を有する重合体が有用である。The ABA type block copolymer elastomer (hereinafter referred to as block elastomer) used in the present invention includes a hard polymer A and a soft polymer B (A: B).
= 10-65: 90-35% by weight, preferably A: B =
15 to 30: 85 to 70% by weight), which is an ABA type structure elastomer. The A block is a hard polymer of a vinyl compound such as styrene and methylstyrene, and has a glass transition temperature of 70 ° C. or higher (preferably 90 ° C.).
Polymers having an average molecular weight of about 1000 to 500,000 (preferably 10,000 to 100,000) are useful. The B block is, for example, a soft polymer of a conjugated diene compound such as butadiene and isoprene, and has a glass transition temperature of -100 to 30 ° C (preferably -90 to -70 ° C), and is about 4500 to 10 ° C.
Polymers having an average molecular weight of 00000 (preferably 50,000 to 500,000) are useful.
【０００９】上記のブロックエラストマーとともに油性
連続相を形成するのに用いられる油成分としては、ブロ
ックエラストマーのＢブロックと相溶性を有し、Ａブロ
ックとは非相溶性であり、かつ室温で液状の油状物質、
例えばマシン油、シリンダー油、トランス油、ロジン
油、液状イソプレン、または各種の流動パラフィン等が
挙げられ、好ましくは液状イソプレン、流動パラフィン
である。また、上記油状物質に、加熱により油状形態を
示す物質〔例えば、融点１２０℃以下（好ましくは３０
〜７０℃）のパラフィンワックス、融点１５０℃以下
（好ましくは５０〜１００℃）のワックス状の低分子量
ポリエチレン等〕を添加した混合物も、本発明の油成分
として有用である。The oil component used to form the oily continuous phase with the block elastomer is compatible with the B block of the block elastomer, incompatible with the A block, and liquid at room temperature. Oily substance,
Examples thereof include machine oil, cylinder oil, trans oil, rosin oil, liquid isoprene, and various liquid paraffins, and liquid isoprene and liquid paraffin are preferable. In addition, a substance which exhibits an oily form upon heating to the above oily substance [for example, a melting point of 120 ° C. or lower (preferably 30
To 70 ° C.), a wax-like low molecular weight polyethylene having a melting point of 150 ° C. or less (preferably 50 to 100 ° C.)] are also useful as the oil component of the present invention.
【００１０】当該油成分の配合量は、上記ブロックエラ
ストマー１００重量部に対して、通常５０〜１０００重
量部、好ましくは８０〜５００重量部である。この範囲
が後記Ｗ／Ｏ型エマルジョンの油性連続相を形成するの
に有効であり、膏体中の含水量と、その要求される柔軟
度の関係によって決定される。The blending amount of the oil component is usually 50 to 1000 parts by weight, preferably 80 to 500 parts by weight, based on 100 parts by weight of the block elastomer. This range is effective for forming the oily continuous phase of the W / O type emulsion described below, and is determined by the relationship between the water content in the plaster and the required flexibility.
【００１１】本発明に用いられる粘着付与成分として
は、ロジンおよび変性ロジン、石油系樹脂、クマロンイ
ンデン樹脂、メチルインデン樹脂、ポリテルペン樹脂、
ポリスチレン樹脂、ヒドロアビエチルアルコール、ポリ
ブテン、液状ポリイソブチレン等が挙げられ、好ましく
は変性ロジン、石油系樹脂、ポリブテンである。当該粘
着付与成分は、上記エラストマーと油成分とからなる系
に含ませるが、上記ブロックエラストマー１００重量部
に対して、通常５０〜２５０重量部、好ましくは１００
〜２００重量部である。As the tackifying component used in the present invention, rosin and modified rosin, petroleum resin, coumarone indene resin, methyl indene resin, polyterpene resin,
Examples thereof include polystyrene resin, hydroabietyl alcohol, polybutene, liquid polyisobutylene, and the like, and modified rosin, petroleum resin, and polybutene are preferable. The tackifying component is contained in the system composed of the elastomer and the oil component, but is usually 50 to 250 parts by weight, preferably 100 parts by weight with respect to 100 parts by weight of the block elastomer.
~ 200 parts by weight.
【００１２】本発明で用いられる温感刺激剤としては、
例えばノニル酸ワニリルアミド、トウガラシエキス、ト
ウガラシ末、トウガラシチンキ、カプサイシン、ニコチ
ン酸ベンジル、ペラルゴン酸等が挙げられ、好ましくは
ノニル酸ワニリルアミド、トウガラシエキスである。な
お、これらは単独で用いてもよいし、２種以上を併用し
てもよい。The warming stimulant used in the present invention includes:
Examples thereof include nonyl acid vanillyl amide, capsicum extract, capsicum powder, capsicum tincture, capsaicin, benzyl nicotinate, pelargonic acid, and the like, and nonyl acid vanillyl amide and capsicum extract are preferable. In addition, these may be used individually and may use 2 or more types together.
【００１３】当該温感刺激剤は、その温感刺激効果が発
現される量を配合すればよく、例えば、ノニル酸ワニリ
ルアミドを単独使用する場合には、膏体全量に対して、
好ましくは０．００３〜０．０３重量％、より好ましく
は０．００７〜０．０２重量％であり、トウガラシエキ
スを単独使用する場合には、好ましくは０．１〜１．０
重量％、より好ましくは０．２〜０．７重量％である。
これらを併用する場合には、トウガラシエキス中の有効
成分量とノニル酸ワニリルアミドの合計重量％がノニル
酸ワニリルアミド単独使用の重量％とするのが好まし
い。また、上記以外の温感刺激剤を使用する場合にも、
その有効成分量がノニル酸ワニリルアミド単独の重量％
と同レベル位とすることが好ましい。The warming stimulant may be blended in such an amount that the warming stimulating effect is exhibited. For example, when nonyl acid vanillyl amide is used alone,
It is preferably 0.003 to 0.03% by weight, more preferably 0.007 to 0.02% by weight, and when the capsicum extract is used alone, it is preferably 0.1 to 1.0.
%, More preferably 0.2 to 0.7% by weight.
When these are used in combination, the total amount by weight of the active ingredient and nonyl acid vanillyl amide in the capsicum extract is preferably the weight percentage by using nonyl acid vanillyl amide alone. Also, when using a warming stimulant other than the above,
The amount of the active ingredient is wt% of nonyl acid vanillyl amide alone
It is preferable to set the same level.
【００１４】本発明の膏体には、上記温感刺激剤以外に
他の薬剤（薬効成分）を含有させてもよく、例えば、サ
リチル酸メチル、サリチル酸グリコール、メントール、
カンフル、チモール、ハッカ油、ボルネオール、ロート
エキス、テレピン油、酢酸トコフェロール、グリチルレ
チン酸、抗ヒスタミン剤（ジフェンヒドラミン等）、生
薬（オオバク、サンシシ等）等が挙げられ、好ましくは
サリチル酸メチル、サリチル酸グリコール、ｌ−メント
ール、ｄｌ−カンフル、ハッカ油、酢酸トコフェロール
である。これらは必要に応じて１種または２種以上が配
合される。上記薬剤の配合量は、膏体全量に対して、好
ましくは０．１〜１０重量％、より好ましくは１〜５重
量％である。The plaster of the present invention may contain other drugs (medicinal components) in addition to the above-mentioned warming stimulant, for example, methyl salicylate, glycol salicylate, menthol,
Examples include camphor, thymol, peppermint oil, borneol, fungal extract, turpentine oil, tocopherol acetate, glycyrrhetinic acid, antihistamines (diphenhydramine, etc.), crude drugs (oak, sanshishi, etc.), etc., preferably methyl salicylate, glycol salicylate, 1-menthol. , Dl-camphor, peppermint oil, and tocopherol acetate. These may be used alone or in combination of two or more. The amount of the above-mentioned drug to be blended is preferably 0.1 to 10% by weight, more preferably 1 to 5% by weight, based on the total amount of the plaster.
【００１５】本発明においては、膏体に吸熱性、保形
性、透湿性、収斂性および過度な自己支持性等の機能的
あるいは物理的特性を付与し、膏体中の薬効をより有効
に機能させる目的で、無機質粉末助剤を使用することが
できる。具体的には、カオリン、クレー、タルク、炭酸
カルシウム、亜鉛華、チタン白等が挙げられ、好ましく
はカオリン、タルク、炭酸カルシウム、チタン白であ
る。当該無機質粉末助剤の配合量は、膏体全量を１００
重量部とした時に、通常５〜５０重量部、好ましくは１
０〜３０重量部とするのがよい。In the present invention, the plaster is endowed with functional or physical properties such as heat absorption, shape retention, moisture permeability, astringency and excessive self-supporting property, so that the medicinal effect in the plaster can be made more effective. Inorganic powder aids can be used for functional purposes. Specific examples include kaolin, clay, talc, calcium carbonate, zinc white, titanium white, and the like, with kaolin, talc, calcium carbonate, and titanium white being preferred. The amount of the inorganic powder auxiliary agent is 100, based on the total amount of plaster.
When the amount is parts by weight, it is usually 5 to 50 parts by weight, preferably 1
The amount is preferably 0 to 30 parts by weight.
【００１６】本発明においては、含水率が膏体全量に対
して１０〜５０重量％であることが必要である。含水率
が５０重量％を越えると、水の蒸発による冷却効果が大
きくなるために、十分な血行促進作用が得られない。ま
た、１０重量％未満であると、同一濃度の温感刺激剤量
であっても、血行促進作用が十分には得られない。ま
た、水粒子は油性連続相中に乳化分散している（Ｗ／Ｏ
型エマルジョン）ことが必要である。In the present invention, it is necessary that the water content is 10 to 50% by weight based on the total amount of paste. If the water content exceeds 50% by weight, the cooling effect due to the evaporation of water becomes large, so that a sufficient blood circulation promoting action cannot be obtained. On the other hand, if the amount is less than 10% by weight, the blood circulation promoting effect cannot be sufficiently obtained even with the same concentration of the warming stimulant. The water particles are emulsified and dispersed in the oily continuous phase (W / O
Type emulsion) is required.
【００１７】前記のＷ／Ｏ型エマルジョンを生成させる
ために乳化剤等が用いられ、前記ブロックエラストマー
と油成分と粘着付与成分と無機質粉末助剤とからなる油
性連続相に対して、乳化された無数の水粒子の分散相を
形成して、Ｗ／Ｏ型エマルジョンの形態を安定に保持す
る性質の乳化剤を用いることが好ましい。An emulsifier or the like is used to form the W / O type emulsion, and a myriad of emulsified emulsions are added to the oily continuous phase consisting of the block elastomer, the oil component, the tackifying component, and the inorganic powder auxiliary agent. It is preferable to use an emulsifier having the property of forming a dispersed phase of water particles and stably maintaining the morphology of the W / O type emulsion.
【００１８】この種の乳化剤としては、非イオン性の界
面活性剤が特に有効であり、例えばポリエチレングリコ
ールオレイルエーテル、ポリエチレングリコールノニル
フェニルエーテル、ポリエチレングリコールドデシルフ
ェニルエーテル、ソルビタンモノラウレート、ソルビタ
ンモノオレエート等が挙げられ、好ましくはポリエチレ
ングリコールオレイルエーテル、ポリエチレングリコー
ルノニルフェニルエーテル、ソルビタンモノオレエート
である。当該乳化剤の配合量は、膏体中の含水量によっ
て異なるが、水１００重量部に対して通常１〜２０重量
部、好ましくは５〜１０重量部である。As the emulsifier of this type, a nonionic surfactant is particularly effective, and examples thereof include polyethylene glycol oleyl ether, polyethylene glycol nonyl phenyl ether, polyethylene glycol dodecyl phenyl ether, sorbitan monolaurate and sorbitan monooleate. And the like, and preferably polyethylene glycol oleyl ether, polyethylene glycol nonyl phenyl ether, sorbitan monooleate. The compounding amount of the emulsifier varies depending on the water content in the plaster, but is usually 1 to 20 parts by weight, preferably 5 to 10 parts by weight with respect to 100 parts by weight of water.
【００１９】なお、この他にも必要に応じて、ｐＨを弱
酸性に保つための有機酸（例えばクエン酸等）、乳化助
剤としての高級脂肪酸金属塩（例えばステアリン酸マグ
ネシウム等）、エチルパラベン等の防腐剤、硫黄等の酸
化防止剤等を適当量配合することができる。In addition to these, if necessary, an organic acid (eg citric acid) for keeping pH weakly acidic, a higher fatty acid metal salt (eg magnesium stearate etc.) as an emulsification aid, ethyl paraben. An appropriate amount of an antiseptic such as the above and an antioxidant such as sulfur can be added.
【００２０】また、支持体上に上記膏体層を設け、さら
に膏体層上に剥離ライナーを設けることにより貼付剤が
得られる。A patch is obtained by providing the above-mentioned plaster layer on a support and further providing a release liner on the plaster layer.
【００２１】支持体としては、合成繊維、再生繊維、天
然繊維（例えばポリエステル、ポリプロピレン、ウレタ
ン、レーヨン、コットン等）よりなる不織布、織布、ニ
ット、またはウレタン、軟質塩化ビニル等の合成樹脂フ
ィルム等を使用することができる。As the support, synthetic fibers, regenerated fibers, non-woven fabrics made of natural fibers (for example, polyester, polypropylene, urethane, rayon, cotton, etc.), woven fabrics, knits, synthetic resin films such as urethane, soft vinyl chloride, etc. Can be used.
【００２２】剥離ライナーの材料としては、プラスチッ
クフィルム、紙等が挙げられるが、薬剤、油成分の吸着
や、変形等の点から、ポリエステルフィルム、ポリエス
テルフィルムラミネート品が好ましい。上記材料の表面
に、剥離処理（例えば、シリコーン樹脂、フッ素樹脂等
による処理等）を行うことにより、当該剥離ライナーが
得られる。Examples of the material for the release liner include plastic films and papers, but polyester films and polyester film laminated products are preferred from the viewpoints of adsorption of chemicals and oil components, deformation and the like. The release liner is obtained by subjecting the surface of the above material to a release treatment (for example, a treatment with a silicone resin, a fluororesin or the like).
【００２３】支持体の厚さは、好ましくは１００〜１０
００μｍ、剥離ライナーの厚さは、好ましくは１２〜１
００μｍである。また、膏体層の厚さは、好ましくは
０．１〜２ｍｍ（好ましくは１００〜２０００g/m2）で
ある。The thickness of the support is preferably 100 to 10
00 μm, the thickness of the release liner is preferably 12 to 1
It is 00 μm. The thickness of the plaster layer is preferably 0.1 to 2 mm (preferably 100 to 2000 g / m 2 ).
【００２４】本発明の膏体は、例えば、ブロックエラス
トマーと油成分と粘着付与成分を加熱して溶解混合し、
これに薬剤、乳化剤を添加混合して、８０〜１００℃と
し、さらに水を添加して乳化を行い、最後に無機質粉末
助剤を添加混合する方法等により得られる。次いで、上
記膏体を、温度８０〜１００℃の間で塗工可能な粘性に
調整し、支持体上に直写、もしくは剥離ライナー上に転
写を行うことにより、貼付剤を製造することができる。
なお、膏体の配合手順については、上記に限定されず、
設備に応じて手順を変えてもよい。The plaster of the present invention is prepared, for example, by heating a block elastomer, an oil component and a tackifying component to dissolve and mix them,
A drug and an emulsifier are added to and mixed with the mixture to obtain a temperature of 80 to 100 ° C., water is further added to emulsify, and finally, an inorganic powder auxiliary agent is added and mixed to obtain the mixture. Then, the plaster can be prepared by adjusting the viscosity of the plaster to a coatable viscosity at a temperature of 80 to 100 ° C. and directly copying it on a support or transferring it on a release liner. .
Incidentally, the mixing procedure of the plaster is not limited to the above,
The procedure may be changed depending on the equipment.
【００２５】[0025]
【実施例】以下の実施例により本発明をより詳細に説明
するが、これらに限定されるものではない。また、本文
中に部とあるのはすべて重量部を示す。The present invention will be described in more detail with reference to the following examples, which should not be construed as limiting the invention. All parts in the text refer to parts by weight.
【００２６】実施例１ スチレン−イソプレン−スチレンブロックエラストマー
（スチレン：イソプレン＝１４：８６）１００部、流動
パラフィン１００部、石油系樹脂１５０部、ポリブテン
２０部を１５０℃にて加熱混合し、これにソルビタンモ
ノオレエート（ＨＬＢ：４）２０部、ノニル酸ワニリル
アミド０．０８部、サリチル酸メチル５部、ｌ−メント
ール１０部を加えて９５℃とし、精製水２２０部、クエ
ン酸０．８部を撹拌下に滴下して乳化混合し、沈降炭酸
カルシウム１００部、エチルパラベン１部、硫黄０．５
部を加えて混合して膏体を得た。これを８００g/m2にな
るようにポリエステル不織布上に展延し、ポリエステル
セパレーターにて覆い、貼付剤を得た。（含水率３０重
量％）Example 1 100 parts of styrene-isoprene-styrene block elastomer (styrene: isoprene = 14: 86), 100 parts of liquid paraffin, 150 parts of petroleum resin, and 20 parts of polybutene were heated and mixed at 150.degree. 20 parts of sorbitan monooleate (HLB: 4), 0.08 part of nonyl acid vanillyl amide, 5 parts of methyl salicylate and 10 parts of l-menthol were added to 95 ° C., and 220 parts of purified water and 0.8 part of citric acid were stirred. 100 parts of precipitated calcium carbonate, 1 part of ethyl paraben, 0.5 of sulfur
Parts were added and mixed to obtain a plaster. This was spread on a polyester non-woven fabric so as to have a weight of 800 g / m 2 and covered with a polyester separator to obtain a patch. (Water content 30% by weight)
【００２７】実施例２ 薬剤部数をノニル酸ワニリルアミド０．０６５部、サリ
チル酸メチル４部、ｌ−メントール８部とし、精製水を
９０部とした以外は実施例１と同様にして、膏体を得、
さらに貼付剤を得た。（含水率１５重量％）Example 2 A plaster was obtained in the same manner as in Example 1 except that the drug parts were 0.065 parts of nonyl acid vanillylamide, 4 parts of methyl salicylate and 8 parts of 1-menthol, and 90 parts of purified water. ,
Furthermore, a patch was obtained. (Water content 15% by weight)
【００２８】実施例３ 薬剤部数をノニル酸ワニリルアミド０．１０部、サリチ
ル酸メチル６．３部、ｌ−メントール１２．５部とし、
精製水を４００部とした以外は実施例１と同様にして、
膏体を得、さらに貼付剤を得た。（含水率４４重量％）Example 3 The drug parts were set to 0.10 parts of nonyl acid vanillyl amide, 6.3 parts of methyl salicylate, and 12.5 parts of 1-menthol.
In the same manner as in Example 1 except that 400 parts of purified water was used,
A plaster and a patch were obtained. (Water content 44% by weight)
【００２９】実施例４ 実施例１において、ノニル酸ワニリルアミド０．０８部
のかわりに、トウガラシエキス１．５部を用いた以外は
実施例１と同様にして、膏体を得、さらに貼付剤を得
た。（含水率３０重量％）Example 4 A plaster was obtained in the same manner as in Example 1 except that 1.5 parts of capsicum extract was used in place of 0.08 part of nonyl acid vanillyl amide. Obtained. (Water content 30% by weight)
【００３０】比較例１ 薬剤部数をノニル酸ワニリルアミド０．０６部、サリチ
ル酸メチル３．７部、ｌ−メントール７．４部とし、精
製水を３５部とした以外は実施例１と同様にして、膏体
を得、さらに貼付剤を得た。（含水率６重量％）Comparative Example 1 The procedure of Example 1 was repeated except that the drug parts were 0.06 parts of nonyl acid vanillyl amide, 3.7 parts of methyl salicylate and 7.4 parts of l-menthol, and 35 parts of purified water. A plaster and a patch were obtained. (Water content 6% by weight)
【００３１】比較例２ 薬剤部数をノニル酸ワニリルアミド０．１２部、サリチ
ル酸メチル７．６部、ｌ−メントール１５部とし、精製
水を６００部とした以外は実施例１と同様にして、膏体
を得、さらに貼付剤を得た。（含水率５４重量％）Comparative Example 2 A plaster was prepared in the same manner as in Example 1 except that the drug parts were 0.12 parts of nonyl acid vanillyl amide, 7.6 parts of methyl salicylate, 15 parts of l-menthol, and 600 parts of purified water. To obtain a patch. (Water content 54% by weight)
【００３２】実験例１ 上記実施例１〜３、比較例１〜２の貼付剤（１０×１０
cm角としたもの）をパネラー（３人）の両肩に貼付し、
貼付後、一定時間毎にパネラーの皮膚表面温度をサーモ
グラフィで測定し、測定値の平均値を出した。この結果
を図１に示す。なお、図１は、縦軸に貼付前の皮膚表面
温度と貼付後の皮膚表面温度の温度差〔即ち、（貼付後
の皮膚表面温度）−（貼付前の皮膚表面温度）〕、横軸
に貼付時間を示すグラフである。Experimental Example 1 Patches of Examples 1 to 3 and Comparative Examples 1 and 2 (10 × 10
Put the square ones) on both shoulders of the panelists (3 people),
After application, the skin surface temperature of the panel was measured by thermography at regular intervals, and the average of the measured values was calculated. The result is shown in FIG. In FIG. 1, the vertical axis represents the temperature difference between the skin surface temperature before application and the skin surface temperature after application [that is, (skin surface temperature after application)-(skin surface temperature before application)], and the horizontal axis. It is a graph which shows sticking time.
【００３３】図１より、含水率が１０〜５０重量％内に
ある実施例１〜３では、貼付前の皮膚表面温度と貼付後
の皮膚表面温度の温度差が１℃以上あり、血行促進効果
が十分あるものと考えられる。これに対し、含水率の低
い比較例１では当該温度差があまり大きくならず、含水
率が高い比較例２では貼付部位を冷やし過ぎる傾向にあ
り、どちらも血行促進効果上、好ましい結果ではなかっ
た。According to FIG. 1, in Examples 1 to 3 in which the water content is within 10 to 50% by weight, the temperature difference between the skin surface temperature before application and the skin surface temperature after application is 1 ° C. or more, and the blood circulation promoting effect is obtained. Is considered to be sufficient. On the other hand, in Comparative Example 1 having a low water content, the temperature difference was not so large, and in Comparative Example 2 having a high water content, the application site tended to be overcooled, neither of which was a preferable result in terms of the blood circulation promoting effect. .
【００３４】比較例３ 精製水５５部にノニル酸ワニリルアミド０．０１２部、
サリチル酸メチル０．７６部、ｌ−メントール１．５３
部とポリオキシエチレンソルビタンモノオレエート１
部、硫酸アルミニウム・カリウム１２水和塩０．５部を
分散混合し、これに、グリセリン中にポリアクリル酸ナ
トリウム１２部とカオリン１０部を分散混合させた液を
加えて撹拌混合し、膏体を得た。これを１２００g/m2に
なるようにポリエステル不織布上に展延し、ポリプロピ
レンセパレーターにて覆い、水溶性パップ剤を得た。
（含水率６８重量％）Comparative Example 3 55 parts of purified water and 0.012 part of nonyl acid vanillyl amide,
Methyl salicylate 0.76 parts, l-menthol 1.53
Parts and polyoxyethylene sorbitan monooleate 1
Parts, and 0.5 parts of aluminum sulfate / potassium dodecahydrate were dispersed and mixed, to which was added a liquid in which 12 parts of sodium polyacrylate and 10 parts of kaolin were mixed and mixed in glycerin, and the mixture was stirred and mixed to give a plaster. Got This was spread on a polyester non-woven fabric so as to be 1200 g / m 2 and covered with a polypropylene separator to obtain a water-soluble poultice.
(Water content 68% by weight)
【００３５】比較例４ ポリシス−イソプレンゴム４０部、スチレン−イソプレ
ン−スチレンブロックエラストマー１５部、流動パラフ
ィン１０部、ポリテルペン樹脂３０部、亜鉛華１０部を
１００℃にて加熱混合し、これにノニル酸ワニリルアミ
ド０．１２部、サリチル酸グリコール１０部、ｌ−メン
トール３部を添加して混合し、膏体を得た。これを２０
０g/m2になるようにポリエステル織布上に展延し、紙セ
パレーターにて覆い、プラスター剤を得た。Comparative Example 4 40 parts of polycis-isoprene rubber, 15 parts of styrene-isoprene-styrene block elastomer, 10 parts of liquid paraffin, 30 parts of polyterpene resin and 10 parts of zinc white were heated and mixed at 100 ° C., and nonyl acid was added thereto. 0.12 parts of vanillyl amide, 10 parts of glycol salicylate, and 3 parts of 1-menthol were added and mixed to obtain a plaster. 20 this
It was spread on a polyester woven fabric so as to be 0 g / m 2 and covered with a paper separator to obtain a plaster agent.
【００３６】実験例２ 実施例１と比較例３、４のサンプル（１０×１０cm角と
したもの）をパネラー（３人）の両肩に貼付し、貼付
後、一定時間毎に貼付時の刺激感、皮膚表面温度、血流
量を測定（評価）し、平均値を出した。Experimental Example 2 The samples of Example 1 and Comparative Examples 3 and 4 (10 × 10 cm square) were attached to both shoulders of panelists (3 persons), and after the application, irritation at the time of application at regular intervals. The feeling, skin surface temperature, and blood flow were measured (evaluated), and the average value was calculated.
【００３７】なお、貼付時の刺激感は、パネラーの感覚
によって下記基準により評価した。 ０：全く感じない， １：弱い， ２：やや弱い， ３：やや強い， ４：強い， ５：かなり強い 皮膚表面温度は、サーモグラフィを用いて測定した。血
流量は、ドップラー血流計を用いて測定した。The sensation of irritation at the time of application was evaluated according to the following criteria according to the feeling of the panelists. 0: Not felt at all, 1: Weak, 2: Moderately weak, 3: Moderately strong, 4: Strong, 5: Fairly strong The skin surface temperature was measured using thermography. The blood flow rate was measured using a Doppler blood flow meter.
【００３８】上記結果をそれぞれ図２〜図４に示す。こ
こで、図２は、縦軸に刺激感、横軸に貼付時間を示すグ
ラフである。図３は、縦軸に貼付前の皮膚表面温度と貼
付後の皮膚表面温度の温度差、横軸に貼付時間を示すグ
ラフである。図４は、縦軸に血流量、横軸に貼付時間を
示すグラフである。The above results are shown in FIGS. Here, FIG. 2 is a graph showing the feeling of stimulation on the vertical axis and the application time on the horizontal axis. FIG. 3 is a graph showing the temperature difference between the skin surface temperature before application and the skin surface temperature after application on the vertical axis, and the application time on the horizontal axis. FIG. 4 is a graph showing the blood flow on the vertical axis and the application time on the horizontal axis.
【００３９】図２より、実施例１に対して、同じ薬剤濃
度の水溶性基剤の比較例３は、貼付初期では同じ刺激感
はあるが、持続性の点でやや劣り、またプラスター剤の
比較例４では貼付初期の立ち上がりが遅く、しかも持続
性もあまり良くなかった。また、図３〜４の皮膚表面温
度変化、血流量変化からみると、実施例１では、皮膚温
度上昇、血流量の上昇が認められたが、比較例３，４で
は殆ど血行促進を裏付けるデータは認められなった。As can be seen from FIG. 2, Comparative Example 3 of the water-soluble base having the same drug concentration had the same sensation of sensation at the initial stage of application as compared with Example 1, but was slightly inferior in terms of persistence, and was less than that of plaster. In Comparative Example 4, the rise in the initial stage of application was slow and the durability was not very good. In addition, from the skin surface temperature changes and blood flow changes of FIGS. 3 to 4, in Example 1, an increase in skin temperature and an increase in blood flow were observed, but in Comparative Examples 3 and 4, data supporting almost all blood circulation promotion were obtained. Was not recognized.
【００４０】実験例３ 実施例１と比較例３について粘着性の比較を行い、その
結果を表１に示す。粘着性は、貼付剤をフェノール樹脂
板およびパネラー（３人）の背中の皮膚に貼付して、貼
付後１０分後の粘着力を測定し、平均値を出した。ま
た、実用粘着性としては、パネラーの両肩に貼付剤を貼
付し、８時間後の剥がれの有無について判定した。な
お、粘着力は、剥離速度３００mm／分、温度２３℃、相
対湿度６５％の条件下で１８０°剥離にて測定した。Experimental Example 3 The adhesive properties of Example 1 and Comparative Example 3 were compared, and the results are shown in Table 1. Regarding the adhesiveness, the patch was applied to the phenol resin plate and the skin on the backs of panelists (three people), and the adhesive force was measured 10 minutes after the application, and the average value was calculated. Also, as the practical adhesiveness, the patch was applied to both shoulders of the panelist, and the presence or absence of peeling after 8 hours was determined. The adhesive strength was measured by 180 ° peeling under the conditions of a peeling speed of 300 mm / min, a temperature of 23 ° C. and a relative humidity of 65%.
【００４１】[0041]
【表１】 [Table 1]
【００４２】その結果、水溶性基剤の比較例３に対し、
実施例１は非常に良好な粘着性を有していた。なお、比
較例３について固定用の補助テープを使用したところ、
実用粘着性は良くなったが、使用時の違和感が大きく、
不快であった。As a result, in comparison with Comparative Example 3 of the water-soluble base,
Example 1 had very good tack. In addition, when the auxiliary tape for fixation was used for Comparative Example 3,
Practical tackiness has improved, but a lot of discomfort when used,
It was uncomfortable.
【００４３】実験例４ 実施例１（ノニル酸ワニリルアミド０．０１重量％含
有）と、市販プラスター剤（市販品Ａ：ノニル酸ワニリ
ルアミド０．０８重量％含有、市販品Ｂ：トウガラシエ
キス１．５重量％含有）との実用性を比較した。試験方
法としては、実施例１の貼付剤（１０×１０cm角とした
もの）、市販品Ａ、市販品Ｂをパネラー（５人）の肩に
６時間貼付し、その刺激感を前記と同様にして判定し
た。また、貼付剤を剥がした後、２４時間後に皮膚カブ
レを以下の基準により評価した。 〔○：カブレなし， △：少しカブレ有り， ×：かな
りカブレ有り〕 これらの結果を表２に示す。Experimental Example 4 Example 1 (containing 0.01% by weight of nonyl acid vanillylamide) and a commercial plaster agent (commercial item A: containing 0.08% by weight of nonyl acid vanillylamide, commercial item B: 1.5% of capsicum extract) %, And the practicality was compared. As the test method, the patch of Example 1 (10 × 10 cm square), the commercial product A and the commercial product B were applied to the shoulders of the panelists (5 people) for 6 hours, and the sensation of stimulation was the same as above. It was judged. In addition, skin peeling was evaluated 24 hours after the patch was peeled off according to the following criteria. [○: No blurring, Δ: Some blurring, ×: Very blurring] These results are shown in Table 2.
【００４４】[0044]
【表２】 [Table 2]
【００４５】上記からわかるように、市販プラスター剤
は温感刺激剤濃度が高いため、ある程度の刺激感を与え
てはいるが、皮膚カブレが生じた。これに対して、実施
例１は市販プラスター剤より温感刺激剤濃度がかなり低
いにもかかわらず、プラスター剤に比べて刺激感が高
く、しかも皮膚カブレは起こらなかった。As can be seen from the above, since the commercially available plaster agent has a high concentration of the warming stimulant, it gives some irritation, but it causes skin irritation. On the other hand, in Example 1, although the concentration of the warming stimulant was considerably lower than that of the commercially available plaster, the feeling of irritation was higher than that of the plaster and no skin rash occurred.
【００４６】[0046]
【発明の効果】本発明の膏体は、低濃度の温感刺激剤量
で従来のパップ剤、プラスター剤にはない、十分な血行
促進作用を発現し、また、皮膚カブレ性、粘着性にも優
れたものである。EFFECTS OF THE INVENTION The plaster of the present invention exerts a sufficient blood circulation promoting action which is not present in conventional poultices and plasters, even at a low concentration of a warming stimulant, and has a skin rash and adhesiveness. Is also excellent.
【図１】貼付時の皮膚表面温度変化を表すグラフであ
る。FIG. 1 is a graph showing changes in skin surface temperature during application.
【図２】貼付時の刺激感を表すグラフである。FIG. 2 is a graph showing a feeling of irritation during application.
【図３】貼付時の皮膚表面温度変化を表すグラフであ
る。FIG. 3 is a graph showing changes in skin surface temperature during application.
【図４】貼付時の血流量変化を表すグラフである。FIG. 4 is a graph showing changes in blood flow during application.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 加藤 宗儀 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Muneyoshi Kato 3-24-1 Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
ー、油成分、粘着付与成分および温感刺激剤が含有され
た油性連続相中に水粒子が乳化、分散されてなり、かつ
その含水率が１０〜５０重量％であることを特徴とする
血行促進型含水膏体。1. Water particles are emulsified and dispersed in an oily continuous phase containing an ABA type block copolymer elastomer, an oil component, a tackifying component and a warming stimulant, and the water content thereof. Is 10 to 50% by weight, and is a blood circulation promoting hydrous plaster.
トウガラシエキスから選ばれる少なくとも１種である請
求項１記載の血行促進型含水膏体。2. The warming stimulant is nonyl acid vanillyl amide,
The blood circulation promoting hydrous plaster according to claim 1, which is at least one selected from capsicum extract.
チル酸メチル、サリチル酸グリコール、ｌ−メントー
ル、ｄｌ−カンフル、ハッカ油、酢酸トコフェロールか
ら選ばれる少なくとも１種が配合されてなる請求項１記
載の血行促進型含水膏体。3. The medicinal component other than the warming stimulant, wherein at least one selected from methyl salicylate, glycol salicylate, l-menthol, dl-camphor, peppermint oil, and tocopherol acetate is blended. Blood circulation-promoting hydrous paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5212634A JPH0759808A (en) | 1993-08-27 | 1993-08-27 | Blood circulation promotion type hydrous plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5212634A JPH0759808A (en) | 1993-08-27 | 1993-08-27 | Blood circulation promotion type hydrous plaster |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0759808A true JPH0759808A (en) | 1995-03-07 |
Family
ID=16625907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5212634A Pending JPH0759808A (en) | 1993-08-27 | 1993-08-27 | Blood circulation promotion type hydrous plaster |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0759808A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003070823A (en) * | 2001-06-19 | 2003-03-11 | Urako Kk | Pack member, medical treatment utensil having pack member, and fixing utensil for pack member |
| JP2006206471A (en) * | 2005-01-26 | 2006-08-10 | Nitto Denko Corp | Tape preparation |
| US7268177B2 (en) * | 2002-04-17 | 2007-09-11 | Laboratoires Urgo | Thermoplastic elastomer-based solid emulsions |
| WO2009123003A1 (en) * | 2008-03-31 | 2009-10-08 | ロート製薬株式会社 | Composition for external application to skin |
| WO2018159478A1 (en) * | 2017-03-01 | 2018-09-07 | ライオン株式会社 | External preparation composition and external preparation |
| KR102090424B1 (en) * | 2019-06-05 | 2020-03-17 | 김철준 | Plaster having improved function |
-
1993
- 1993-08-27 JP JP5212634A patent/JPH0759808A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003070823A (en) * | 2001-06-19 | 2003-03-11 | Urako Kk | Pack member, medical treatment utensil having pack member, and fixing utensil for pack member |
| US7268177B2 (en) * | 2002-04-17 | 2007-09-11 | Laboratoires Urgo | Thermoplastic elastomer-based solid emulsions |
| JP2006206471A (en) * | 2005-01-26 | 2006-08-10 | Nitto Denko Corp | Tape preparation |
| WO2009123003A1 (en) * | 2008-03-31 | 2009-10-08 | ロート製薬株式会社 | Composition for external application to skin |
| WO2018159478A1 (en) * | 2017-03-01 | 2018-09-07 | ライオン株式会社 | External preparation composition and external preparation |
| JPWO2018159478A1 (en) * | 2017-03-01 | 2019-12-19 | ライオン株式会社 | External preparation composition and external preparation |
| KR102090424B1 (en) * | 2019-06-05 | 2020-03-17 | 김철준 | Plaster having improved function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7556823B2 (en) | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl | |
| EP1568365A1 (en) | Warm poultice | |
| WO2006090782A1 (en) | Composition for hydrous adhesive patch for external use and adhesive patch comprising the composition | |
| JP5089933B2 (en) | Water-containing pressure-sensitive adhesive composition and patch using the same | |
| JP2017154989A (en) | S/o type patch | |
| WO1996029062A1 (en) | Cold sheet | |
| JPH09208460A (en) | Cataplasm | |
| JPS5936608A (en) | Novel application drug | |
| JPH0759808A (en) | Blood circulation promotion type hydrous plaster | |
| EP3267982A2 (en) | Fentanyl transdermal delivery system | |
| JPS63145222A (en) | Cataplasm | |
| JPH08225448A (en) | Percutaneously absorptive tape for local anesthetization | |
| JP3723229B2 (en) | External patch | |
| JPH0616542A (en) | Medical adhesive tape or sheet | |
| JPH0338243B2 (en) | ||
| JP2004256396A (en) | Lowly skin-irritating plaster | |
| JP2000256214A (en) | Antiphlogistic-sedative plaster | |
| JP2887548B2 (en) | Hydrous skin external patch with improved usability | |
| JPH078784B2 (en) | Hydrophilic transdermal preparation | |
| JPH07196505A (en) | Percutaneous absorption preparation | |
| JPH0517346A (en) | Agent for medical application | |
| JPH06219947A (en) | Endermism preparation | |
| JPH0582430B2 (en) | ||
| JPS5951215A (en) | Adhesive poultice | |
| JPH0733648A (en) | Medical tape containing anti-i type allergic agent |